86/90Y-NM600在多种小鼠及人类肿瘤模型中的临床前特征
本研究在肺癌、胰腺癌、前列腺癌、肝癌、皮肤癌和淋巴瘤等多种小鼠肿瘤模型中,评价了86Y-NM600的体内生物分布和肿瘤选择性,并用小动物PET/CT进行纵向显像。结果显示各模型均有持续的肿瘤摄取与滞留,胰腺癌和淋巴瘤模型摄取最高,约40-48小时达峰浓度分别为9.34 ± 2.66 %IA/g和9.10 ± 0.13 %IA/g;90Y-NM600毒性研究未见急性毒性组织学征象,血液学参数扰动为一过性,28天后恢复。
要点
- 86Y-NM600在多种肿瘤模型中显示持续肿瘤摄取与滞留,脱靶滞留主要见于肝脏。
- 胰腺癌和淋巴瘤模型肿瘤摄取最高,约40-48小时达峰。
- 90Y-NM600在毒性研究中未见急性毒性组织学征象,血液学扰动为一过性。
核心结论
- NM600是一种诊疗一体化药物,能选择性靶向多种癌症类型,为PET图像引导的靶向放射性核素治疗及与免疫治疗联合提供了独特机会。
研究设计与样本
- 小鼠荷瘤模型(代表肺癌、胰腺癌、前列腺癌、肝癌、皮肤癌和淋巴瘤)静脉注射9.25 MBq 86Y-NM600,用小动物PET/CT纵向显像4-5天。
- 显像后处死小鼠,用自动γ计数器计数肿瘤和感兴趣器官,并估算90Y-NM600每注射活度的吸收剂量(Gy/MBq)。
- 荷B78肿瘤小鼠注射90Y-NM600使肿瘤吸收剂量达2.5 Gy,与等效吸收剂量的外照射放疗比较,以肿瘤体积评价反应。
- 未荷瘤C57BL/6小鼠注射9.25 MBq 90Y-NM600,在注射后5、10和28天分析组织学和全血细胞计数。
主要发现
- PET显像显示所有研究肿瘤模型均有持续的肿瘤累积和滞留,除肝脏外脱靶滞留很少,符合肝胆代谢特征。
- 胰腺癌和淋巴瘤模型肿瘤摄取最高,注射后约40-48小时达峰浓度分别为9.34 ± 2.66 %IA/g(n = 3)和9.10 ± 0.13 %IA/g(n = 3)。
- 上述摄取对应肿瘤剂量估计分别为2.72 ± 0.33 Gy/MBq和2.67 ± 0.32 Gy/MBq。
- 毒性研究中组织学未见急性毒性可见征象,观察到的血液学参数扰动为一过性,28天后恢复至治疗前水平。
关键数值与推荐
- 86Y-NM600注射活度为9.25 MBq,用于小动物PET/CT显像。
- 胰腺癌模型肿瘤摄取峰值9.34 ± 2.66 %IA/g(n = 3),对应肿瘤剂量估计2.72 ± 0.33 Gy/MBq。
- 淋巴瘤模型肿瘤摄取峰值9.10 ± 0.13 %IA/g(n = 3),对应肿瘤剂量估计2.67 ± 0.32 Gy/MBq。
- 90Y-NM600处方使B78肿瘤吸收剂量达2.5 Gy,与外照射放疗等效吸收剂量比较。
- 毒性研究在注射后5、10和28天分析组织学和全血细胞计数。
临床怎么用
- 临床前数据提示NM600可用于PET图像引导的靶向放射性核素治疗,但尚未在人体中验证。
- 肝脏为主要的脱靶滞留器官,临床转化时需关注肝胆代谢相关的剂量分布。
- 血液学毒性表现为一过性,28天后恢复,提示后续临床研究需进行血液学监测。
局限性
- 研究为临床前小鼠模型,结果不能直接外推至人体。
- 毒性研究仅分析组织学和全血细胞计数,未报告其他安全性指标。
- 部分模型样本量较小(如胰腺癌和淋巴瘤模型n = 3)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We characterize the in vivo biodistribution and tumor selectivity of 86Y-NM600, a theranostic alkylphosphocholine radiometal chelate with broad tumor selectivity, in a variety of preclinical cancer models. Methods: Mice bearing flank tumors (representative of lung, pancreatic, prostate, liver, skin, and lymphoid cancers) were injected intravenously with 9.25 MBq of 86Y-NM600 and imaged longitudinally over 4-5 d using small-animal PET/CT. Percentage injected activity per gram (%IA/g) for each volume of interest was measured at each time point for the organs of interest. Mice were euthanized after the final time point, and the tumor and organs of interest were counted with an automatic γ-counter. Absorbed doses delivered by 90Y-NM600 per injected activity (Gy/MBq) were estimated. Mice bearing B78 flank tumors were injected with a prescription of 90Y-NM600 that delivered 2.5 Gy of absorbed tumor dose and was compared with an equivalent absorbed dose delivered via external-beam radiotherapy using tumor volume as a measure of response. Histology and complete blood counts were analyzed in naïve C57BL/6 mice that were injected with 9.25 MBq of 90Y-NM600 at 5, 10, and 28 d after injection. Results: PET imaging showed consistent tumor accumulation and retention across all tumor models investigated, with little off-target retention of NM600 except in the liver, as is characteristic of hepatobiliary metabolism. The tumor uptake was highest in the pancreatic and lymphoid cancer models, reaching peak concentrations of 9.34 ± 2.66 %IA/g (n = 3) and 9.10 ± 0.13 %IA/g (n = 3), respectively, at approximately 40-48 h after injection. These corresponded to tumor dose estimates of 2.72 ± 0.33 Gy/MBq and 2.67 ± 0.32 Gy/MBq, respectively. In the toxicity study, there were no visible signs of acute toxicity by histology, and perturbation of hematologic parameters was transient when observed, returning to pretherapy levels after 28 d. Conclusion: NM600 is a theranostic agent with a unique ability to selectively target a variety of cancer types, presenting a unique opportunity for PET image-guided targeted radionuclide therapy and combination with immunotherapies.
引用
- Grudzinski JJ, Hernandez R, Marsh I, et al. Preclinical Characterization of 86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models. J Nucl Med. 2019. PMID: 30954941. doi:10.2967/jnumed.118.224808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。